



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > Rotigotine > Printer-friendly PDF

Rotigotine

Trade Name:

Neupro

Manufacturer/Distributor:

UCB Canada Inc.

www.ucb.com 1-877-504-7363

Classification:

Antiparkinsonian agent / Dopamine agonist

ATC Class:

N02BX - Other dopaminergic agents

Status:

active

Notice of Compliance (yyyy/mm/dd):

2012/03/21

Date Marketed in Canada (yyyy/mm/dd):

2013/09/12

Presentation:

Transdermal patch: 1 mg/24 hr. DIN: 02403897

Transdermal patch: 2 mg/24 hr. DIN: 02403900

Transdermal patch: 3 mg/24 hr. DIN: 02403919

Transdermal patch: 4 mg/24 hr. DIN: 02403927

Transdermal patch: 6 mg/24 hr. DIN: 02403935

Transdermal patch: 8 mg/24 hr. DIN: 02403943

Comments:

Rotigotine is used for treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used both as early therapy, without concomitant levodopa, or as an adjunct to levodopa. This medication has also been approved to treatment of moderate to severe idiopathic restless legs syndrome.

Keywords: rotigotine

transdermal drug administration

parkinson disease

restless legs

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:**Search Terms:**

[A \(37\)](#) | [B \(20\)](#) | [C \(24\)](#) | [D \(37\)](#) | [E \(40\)](#) | [F \(12\)](#) | [G \(11\)](#) | [H \(9\)](#) | [I \(24\)](#) | [K \(1\)](#) | [L \(26\)](#) | [M \(12\)](#) | [N \(7\)](#) | [O \(12\)](#) | [P \(28\)](#) | [R \(14\)](#) | [S \(27\)](#) | [T \(33\)](#) | [U \(4\)](#) | [V \(13\)](#) | [W \(2\)](#) | [Z \(4\)](#)

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Guanfacine HCl</u>	Intuniv XR	Alpha adrenergic receptor agonist for ADHD	2013/08/06
<u>Heparin Sodium</u>	Hepalean	Heparin anticoagulant	
<u>Homatropine</u>	Isopto Homatropine	Mydriatic agent	
<u>Human Papillomavirus Vaccine</u>	Cervarix	Vaccine	2010/02/05
<u>Hydrocodone + phenylephrine + pyrilamine + ammonium chloride</u>	Hycomine Syrup	Narcotic	2011/05/11
<u>Hydrocodone resin with phenyltoloxamine</u>	Tussionex tablets	Narcotic	
<u>Hydromorphone</u>	Dilaudid injection; Dilaudid HP injection	Narcotic	
<u>Hydromorphone hydrochloride</u>	Jurnista	opioid anaglesic	2010/04/13
<u>Hydromorphone hydrochloride</u>	Hydromorph Contin	Opioid analgesic	2011/04/01
<u>Hydroxocobalamin</u>	Cyanokit	Antidote	2011/05/24
<u>Ibuprofen</u>	Caldolor	NSAID	2012/05
<u>Ibuprofen & Methocarbamol</u>	Summit Ultra	Muscle relaxant/analgesic	2012/03/14
<u>Imiquimod</u>	Vyloma	Immune response modifier	2011/05/04

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Indacaterol + glycopyrronium bromide + mometasone</u>	Energair Breezhaler	Asthma medication	2020/11/05
<u>Indacaterol maleate</u>	Onbrez Breezhaler	Long-acting beta 2 agonist	2012/03
<u>Indomethacin</u>	Indomethacin P.D.A.	NSAID	2011/11/15
<u>Infliximab</u>	Avsola	Biological response modifier	2020/06/01
<u>Influenza Vaccine</u>	Intanza	Vaccine	2010/08/01
<u>Influenza Vaccine</u>	Flumist	Vaccine	2010/08/13
<u>Influenza Vaccine</u>	Agriflu	Vaccine	2010/09/01
<u>Influenza vaccine</u>	Fluad	Influenza vaccine	2011/08/25
<u>Insulin aspart + niacinamide</u>	Fiasp	Insulin analogue	2017/04/06
<u>Interferon beta-1b</u>	Extavia	Biologic response modifier	2010/05/17
<u>Ipilimumab</u>	Yervoy	Antineoplastic agent	2012/03
<u>Iron isomaltoside</u>	Monoferic	Iron preparation	2018/06/22
<u>Isatuximab</u>	Sarclisa	Antineoplastic agent, monoclonal antibody	2020/07/03
<u>Isotretinoin</u>	Epuris	Acne therapy	2013-03-14
<u>Ivabradine</u>	Lancora	Cardiac medication	2017/04
<u>Ivacaftor</u>	Kalydeco	Cystic fibrosis transmembrane conductance regulator potentiator	2012/12/01
<u>Ivacaftor + tezacaftor</u>	Symdeko	Cystic Fibrosis Transmembrane Conductance Regulator Correctors and Potentiators	2018/06/27
<u>Ivermectin</u>	Rosiver	Topical rosacea therapy	2015/05/25
<u>Ivermectin</u>	Stromectol	Anthelmintic	2018/11/07
<u>Ixazomib</u>	Ninlaro	Antineoplastic agent	2016/09/21
<u>Ixekizumab</u>	Taltz	Immunomodulator	2018/03/29

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
Ketorolac tromethamine	Acuvail	Topical NSAID	2011/10/01
Lacosamide	Vimpat	Anticonvulsant	2010/10/21
« first ? previous ? 2 3 4 5 6 7 8 9 10 ? next ? last »			

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the xʷmʷkʷyʷm (Musqueam), Skʷwxʷwʷmesh Uʷxwumixw (Squamish Nation), and sʷlʷilwʷtaʷ (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-05-30 18:00): <http://www.dpic.org/druglisting/rotigotine>